Lumixyl Topical Brightening System

The Lumixyl Topical Brightening System is a very good at treating mild to moderate cases of melasma, and can be considered as an option especially for those suffering from recalcitrant melasma unresponsive to previous therapy.

Images


Effects


Grade Level of Evidence
A Double-blind, controlled study with more than 50 participants.
B Controlled study that is single-blind or has less than 50 participants.
C Controlled or comparative study.
D Uncontrolled or observational study.
Grade Effect Size of Effect Comments

C

Melasma treatment

Strong

Excellent efficacy in treating recalcitrant melasma of mild to moderate severity, even in patients who had previously undergone failed treatment.

Looking to buy Lumixyl Topical Brightening System?

Buy from Amazon.com.

Ingredients


Proprietary Oligopeptide (Lumixyl)
NAME ANTIOXIDANT UV PROTECTION COMEDOGENIC IRRITANT SAFETY
PROPRIETARY OLIGOPEPTIDE (LUMIXYL) NO RECORDS FOUND

Clinical Studies


Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.

Products

Lumixyl Topical Brightening System

Trial Design

Open-label, multicenter, uncontrolled

Duration

16 weeks of treatment

Subjects

33 healthy Hispanic females aged between 25-50 years, with mild-to-moderate melasma

Regimen

Morning: Cleansed the face with the antioxidant cleanser, applied the 0.01% decapeptide-12 cream, then applied the 20% buffered glycolic acid lotion, followed by the broad spectrum SPF 30 sunscreen.

Evening: Cleansed the face with the antioxidant cleanser, applied the 0.01% decapeptide-12 cream, then applied the 20% buffered glycolic acid lotion.

The glycolic acid lotion was applied once every other morning from week 0 to week 4, then every morning from week 5 to week 8, then every morning and every other evening from week 9 to week 12, and finally twice daily from week 13 to week 16.

Methods of Assessment

Clinical evaluation of melasma according to the modified melasma area and severity index (MASI)

Standardized digital photography at weeks 0 and 16

Side Effects

3 participants discontinued the study during the first 2 weeks, due to severe irritation. The remaining participants did not report any serious adverse events. Only very mild desquamation was observed in those participants with dry skin types.

Conflicts of Interest

None declared.

Effects observed in this study:

MASI scores indicated that melasma severity improved continuously throughout the 16 weeks of treatment, with close to 36% reduction in severity as early as week 4, and a mean 60% decrease in severity at the end of the study. Standardized before and after photos also demonstrated a marked reduction in the appearance of melasma.

Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.

Products

Lumixyl Topical Brightening System

Trial Design

Uncontrolled case study

Duration

12 or 24 weeks of treatment

Subjects

3 females and 1 male, aged between 30-47 years and with mild-to-moderate melasma

Regimen

Used the antioxidant cleanser and the 0.01% oligopeptide cream twice daily.

Used the 20% glycolic acid lotion every other morning for 2 weeks, then every morning and every other evening for 2 weeks, followed by twice a day for 6 or 18 weeks.

Used the physical sunscreen daily.

Methods of Assessment

Standardized digital photographs taken at baseline, 6, 8, 12 and 24 weeks

Side Effects

No serious adverse events reported. Patients complained of mild dryness that resolved after 4 weeks.

Conflicts of Interest

1 of the 2 authors was an employee of Envy Medical, which markets the Lumixyl products.

Effects observed in this study:

Results ranged from significant fading in the intensity of melasma for 2 patients after 12 and 24 weeks, and nearly complete clearance of melasma for the other 2 patients, after only 6-8 weeks.

A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.

Products

Lumixyl Topical Brightening System

Dove Soap

Trial Design

Double-blind, randomized, placebo-controlled, split-face

Duration

16 weeks of treatment

Subjects

5 healthy women aged between 30-45 years, of Fitzpatrick phototype IV, and with moderate to severe recalcitrant melasma.

Regimen

After washing thoroughly with Dove Soap, participants applied a pea-sized amount of Lumixyl Topical Brightening Creme or its vehicle to the face twice daily.

Methods of Assessment

Physician grading of improvements in the appearance of melasma by comparing digital photographs taken at baseline, 12 weeks and 16 weeks.

Participant and physician grading of overall facial appearance using a 4-point global assessment scale.

Side Effects

No signs of irritation or allergic reaction.

Conflicts of Interest

None declared.

Effects observed in this study:

Melasma scores from both participants and physician graders agreed that subjects showed >40% improvement after 12 weeks, and >50% improvement after 16 weeks. The global assessment scores were also in agreement, showing >70% improvement in the overall appearance of facial skin, compared to up to 15% improvement for the placebo. Importantly, all 5 of the subjects in this study had previously failed to show improvement in melasma after 6 months of treatmetn with a different product, Tri-Luma.